Safety and Pharmacokinetics of REGN2810 (Cemiplimab) (Anti-PD-1) in Japanese Patients With Advanced Malignancies

  • End date
    May 24, 2026
  • participants needed
  • sponsor
    Regeneron Pharmaceuticals
Updated on 19 November 2021


The primary objective of the study is to assess the safety, tolerability, and Pharmacokinetics (PK) of cemiplimab in Japanese patients with advanced malignancies.

The secondary objectives are:

  • To assess the immunogenicity of cemiplimab
  • To evaluate tumor response (objective response rate [ORR] and duration of response [DOR] to cemiplimab monotherapy as first line treatment of Japanese patients with advanced squamous or non-squamous non-small cell lung cancer (NSCLC) (Part 2, cohort A)
  • To evaluate tumor response ORR and DOR to cemiplimab plus chemotherapy as first line treatment of Japanese patients with advanced squamous or non-squamous NSCLC (Part 2, cohort C)

Condition Advanced Malignancies
Treatment Ipilimumab, REGN2810, Cemiplimab, Platinum-doublet chemotherapy
Clinical Study IdentifierNCT03233139
SponsorRegeneron Pharmaceuticals
Last Modified on19 November 2021


Yes No Not Sure

Inclusion Criteria

Disease types under study
Part 1: Histologically or cytologically confirmed diagnosis of malignancy with no alternative standard-of-care therapeutic option
Part 2: Patients with histologically or cytologically documented squamous or non-squamous NSCLC with stage IIIB or IIIC or stage IV disease who received no prior systemic treatment for recurrent or metastatic NSCLC
Patients in Part 2 NSCLC cohorts must have available archival or newly obtained formalin-fixed tumor tissue from a metastatic/recurrent site, which has not previously been irradiated
ECOG (Eastern Cooperative Oncology Group) PS (Performance status) 1 (Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature [eg, light house work or office work]). Note: Patients with ECOG PS >1 are ineligible
Patients must have been born in Japan, and their biological parents and grandparents must all have been of Japanese origin
Willing and able to comply with clinic visits and study-related procedures

Exclusion Criteria

Ongoing or recent (within 5 years) evidence of significant autoimmune disease that requires treatment with systemic immunosuppressive treatments, which may suggest risk for Immune-related adverse event (irAE)s. The following are not exclusionary: vitiligo, childhood asthma that has resolved, residual hypothyroidism that requires only hormone replacement or psoriasis that does not require systemic treatment
Untreated brain metastasis (es) that may be considered active. Patients with previously treated brain metastases may participate provided they are stable, there is no evidence of new or enlarging brain metastases, and the patient does not require any systemic corticosteroids for management of brain metastases within 4 weeks prior to the first dose of cemiplimab
Immunosuppressive corticosteroid doses (>10 mg prednisone daily or equivalent) within 4 weeks prior to the first dose of cemiplimab
Any positive test (ribonucleic acid (RNA) or Deoxyribonucleic acid (DNA) by polymerase chain reaction) for hepatitis B, hepatitis C, or human immunodeficiency virus indicating uncontrolled active or chronic infection
History of pneumonitis or interstitial lung disease
Surgery within 1 month of first dose and radiation therapy within 2 weeks of first dose
Completed palliative radiation therapy within the prior 2 weeks or has not recovered from any medically significant radiation-related Adverse Event (AE)
Patients that have never smoked, defined as smoking 100 cigarettes in a lifetime (Part 2)
Patients with tumors tested positive for epidermal growth factor receptor (EGFR) gene mutations, anaplastic lymphoma kinase (ALK) gene translocations, or ROS1 fusions (Part 2)
Note: Other protocol defined inclusion/exclusion criteria apply
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note